ArrowMark Colorado Holdings LLC Sells 500,144 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ArrowMark Colorado Holdings LLC trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,510,511 shares of the biopharmaceutical company’s stock after selling 500,144 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Halozyme Therapeutics were worth $72,218,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HALO. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System raised its holdings in Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after buying an additional 200 shares during the period. CreativeOne Wealth LLC raised its holdings in Halozyme Therapeutics by 1.6% during the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 294 shares during the period. State of New Jersey Common Pension Fund D lifted its position in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the period. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Finally, Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.89.

Halozyme Therapeutics Price Performance

HALO opened at $61.19 on Friday. The company has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.42 and a beta of 1.26. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $39.79 and a 12-month high of $66.00. The business’s fifty day simple moving average is $60.79 and its 200-day simple moving average is $55.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,697 shares of company stock valued at $1,558,052 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.